Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × lanreotide × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 267 Prednisone 219 enzalutamide 172 Leuprolide 168 Radiotherapy 160 Abiraterone Acetate 153 Magnetic Resonance Spectroscopy 149 bicalutamide 122 Goserelin 121 Androgen Antagonists 109 Radiosurgery 101 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 99 apalutamide 85 gallium 68 PSMA-11 71 abiraterone 69 Specimen Handling 69 darolutamide 58 Gonadotropin-Releasing Hormone 57 Surveys and Questionnaires 54 Biopsy 54 Radiation 53 cabazitaxel 51 Triptorelin Pamoate 51 Brachytherapy 51 pembrolizumab 45 Standard of Care 45 luprolide acetate gel depot 44 Zoledronic Acid 44 Radiotherapy, Intensity-Modulated 42 Estramustine 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01313273 2019-11-22

POSEIDON

Ipsen

Phase 3 Terminated

3 enrolled 4 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡